Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib effect on radiolabeled cG250 or bevacizumab uptake in clear cell renal cell carcinoma
NL-OMON30815Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sorafenib in clear cell renal cell carcinoma (ccRCC) (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoints: Effect of sorafenib on indium-111-cG250 tumor uptake and Effect of sorafenib on indium-111-bevacizumab tumor uptake. Planned start Nov 2006; status: not yet recruiting.
02
Drugs
sorafenib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON30815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30815.